Texas Oncology - Central/South Texas
Welcome,         Profile    Billing    Logout  
 21 Trials 
38 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barve, Minal
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
FANG Ovarian, NCT01309230: A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Completed
2
145
US
Vigil™, formerly known as FANG™ vaccine, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
Gradalis, Inc.
Ovarian Cancer
02/22
02/22
SGT53-02-1, NCT02340117: Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Recruiting
2
28
US
SGT-53, nab-paclitaxel, Abraxane ABI-007, Albumin-bound paclitaxel, Gemcitabine, Gemzar
SynerGene Therapeutics, Inc.
Metastatic Pancreatic Cancer
12/22
12/23
COMPANION-003, NCT05513742: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Active, not recruiting
2
84
US
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
06/24
12/24
BETA-PRIME, NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
2
140
US
AdAPT-001, Checkpoint Inhibitor, Immune
EpicentRx, Inc.
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
12/25
03/27
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Completed
1/2
76
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
10/23
06/24
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
NCT05255484: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated
1/2
24
US
LM-108, An Anti-PD-1 Antibody
LaNova Medicines Limited
Advanced Solid Tumor
10/23
10/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT06187402: A Study of LM-24C5 For Advanced Solid Tumors

Recruiting
1/2
49
US
LM-24C5
LaNova Medicines Limited
Advanced Solid Tumor
06/25
03/26
KEYNOTE A60, NCT04332653: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Active, not recruiting
1/2
215
US
NT-I7, Efineptakin alfa, rhIL-7-hyFc, pembrolizumab (KEYTRUDA®), KEYTRUDA®
NeoImmuneTech, Merck Sharp & Dohme LLC
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
11/24
12/24
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
06/24
06/24
TTX-MC138-002, NCT06260774: Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Recruiting
1/2
20
US
TTX-MC138
TransCode Therapeutics
Advanced Solid Tumor
02/26
02/27
NCT04780217: Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
42
US
T3011
ImmVira Pharma Co. Ltd
Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC, Ovarian Cancer, Endometrial Cancer
03/25
08/25
NCT05731271: A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Active, not recruiting
1/2
111
US
TST003
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
05/25
08/25
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
Acclaim-2, NCT05062980: Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer

Active, not recruiting
1/2
180
US
quaratusugene ozeplasmid, Reqorsa, pembrolizumab, Keytruda, docetaxel, Taxotere, ramucirumab, Cyramza, Investigator's Treatment of Choice
Genprex, Inc.
Non Small Cell Lung Cancer
12/24
12/25
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
1
19
US
TST005
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
09/23
09/23
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
SHR-A1811-I-101, NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
396
US, RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Advanced Solid Tumors
12/25
03/26
NCT04886622: A Study of DT2216 in Relapsed/Refractory Malignancies

Completed
1
20
US
DT2216
Dialectic Therapeutics, Inc
Solid Tumor, Hematologic Malignancy
11/23
11/23
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Completed
1
49
US
NBF-006
Nitto BioPharma, Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
11/23
03/24
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
BP1001-A-101-GynOnc, NCT04196257: BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Recruiting
1
50
US
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Bio-Path Holdings, Inc.
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor
07/24
10/24
NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting
1
240
Europe, Canada, Japan, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors, Neoplasms
10/26
01/27
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Recruiting
1
60
US
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
TH1902-CTR-0001, NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/24
12/24
NCT05103046: First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

Recruiting
1
68
US
UCT-03-008
1200 Pharma, LLC, Translational Research in Oncology
Advanced Solid Tumor
12/24
12/25
KEYNOTE-E65, NCT03881488: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Active, not recruiting
1
100
US
CTX-471, Pembrolizumab (KEYTRUDA®), KEYTRUDA®
Compass Therapeutics, Iqvia Pty Ltd, Merck, Sharp & Dohme, LLC, Rahway, NJ USA
Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
02/25
04/25
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT05861895: A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Recruiting
1
84
US
HF158K1 /Arm 2 mg/m², Infusion, HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m², HF158K1 /Arm 30 mg/m², HF158K1 /Arm 45 mg/m², HF158K1 /Arm 60 mg/m²
HighField Biopharmaceuticals Corporation
Solid Tumors, Adult
04/25
12/25
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28

Download Options